Completed PHASE3 INTERVENTIONAL 3-arm NCT01992094

Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older

A Phase III, Stratified, Randomized, Double-Blind, Multicenter, NonInferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages ≥18 Years of Age

Sponsor: Novartis Vaccines

Conditions Influenza

Interventions QIVc TIV1c TIV2c

Updated 6 times since 2017 Last updated: Nov 2, 2015 Started: Nov 30, 2013 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Influenza, this trial is completed. The trial is conducted by Novartis Vaccines and has accumulated 6 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Vaccines

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Anderson, United States , Austin, United States , Bellevue, United States , Cary, United States , Charlotte, United States , Coral Gables, United States , Council Bluffs, United States , Dakota Dunes, United States , Dallas, United States and 26 more locations